Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (63)

2024

  1. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11

  2. Erratum: Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome medicine (2023) 15 1 (22))

    Genome medicine

  3. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  4. Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

    Digestive and Liver Disease

  5. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy

    Hepatology (Baltimore, Md.), Vol. 80, Núm. 4, pp. 791-806

  6. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  7. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports, Vol. 9, Núm. 5, pp. 1419-1428

  8. Reproductive and pregnancy control in Wilson disease patients in Spain

    European Journal of Gastroenterology and Hepatology, Vol. 36, Núm. 11, pp. 1340-1345

  9. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597